Cervical Cancer Survival Influenced by Presence of Diabetes Mellitus
the Cancer Therapy Advisor take:
Diabetes mellitus (DM) was determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer (CC), according to an article published online in the journal The Oncologist.
In this study, 2,946 patients diagnosed with primary stage 2-2A CC and received curative treatments between 2004 and 2008 were identified from the nationwide Taiwan Cancer Registry database. In total, 284 (9.6%) patients had DM.
Results showed patients with DM had significantly lower 5-year cervical cancer-specific survival (CSS) and overall survival (OS) rates compared to patients without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%, respectively).
The investigators found that DM remained an independent unfavorable prognostic factor for CSS (aHR, 1.46) and OS (aHR, 1.55), after adjusting for clinicopathologic variables and comorbidities.
The study’s findings indicated that the risk of cancer recurrence and death in patients with early stage CC may be increased by DM, even after receiving curative treatments.
Diabetes mellitus determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer